NASDAQ:CGON CG Oncology Q3 2026 Earnings Results & Report $75.27 +10.47 (+16.16%) As of 11:01 AM Eastern This is a fair market value price provided by Massive. Learn more. CG Oncology beat analyst expectations on both earnings and revenue in its Q3 2026 results, released November 6, 2026. The company reported EPS of -$0.64 versus the -$0.8341 consensus estimate, while revenue of $1.60 million topped the $548 thousand estimate by $1.06 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 6, 2026TimeBefore Market OpensConference Call8:30 AM ET CG Oncology EPS ResultsActual EPS-$0.64Consensus EPS -$0.8341Beat/MissBeat by +$0.1941One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersCG Oncology Revenue ResultsActual Revenue$1.60 millionExpected Revenue$548 thousandBeat/MissBeat by +$1.06 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) CG Oncology Q3 2026 Earnings FAQ Did CG Oncology beat earnings estimates for Q3 2026? CG Oncology (NASDAQ:CGON) reported earnings of -$0.64 per share for Q3 2026, beating the consensus estimate of -$0.8341. The report was announced on Friday, November 6, 2026. What was CG Oncology's revenue for Q3 2026? CG Oncology reported revenue of $1.60 million for Q3 2026, against a consensus estimate of $548 thousand. CG Oncology Earnings HeadlinesEarnings Flash (CGON) CG Oncology, Inc. Reports Q3 Revenue $1.6M1 hour ago | marketscreener.comMCG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates2 hours ago | globenewswire.comMy prediction for December 8thElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 6 at 1:00 AM | Behind the Markets (Ad)CG Oncology (CGON) Projected to Post Quarterly Earnings on FridayNovember 6 at 1:27 AM | americanbankingnews.comCG Oncology, Inc. (NASDAQ:CGON) Stock Now Rated "Moderate Buy" by Sell-Side AnalystsNovember 5 at 2:29 AM | americanbankingnews.comCG Oncology: A Second-Mover Advantage In Bladder-Sparing TherapyOctober 27, 2026 | seekingalpha.comSee More CG Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CG Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CG Oncology and other key companies, straight to your email. Email Address About CG OncologyCG Oncology (NASDAQ:CGON) (NASDAQ: CGON) is a clinical-stage biotechnology company focused on developing therapies for bladder cancer and other cancers affecting the urinary tract. The company is developing medicines designed to stimulate the immune system and target tumor cells within the bladder. Its lead product candidate is cretostimogene grenadenorep, an investigational intravesical therapy based on an oncolytic adenovirus. The treatment is designed to be administered directly into the bladder, where it may selectively infect cancer cells, promote their destruction and activate an immune response against the tumor. CG Oncology has primarily studied the therapy in patients with non-muscle-invasive bladder cancer, including patients whose disease has not responded adequately to standard treatments. CG Oncology was founded in 2010 and is headquartered in Irvine, California. The company conducts clinical development activities in the United States and has evaluated its therapies through multicenter studies involving patients and research sites in the U.S. and other regions. Its work remains centered on advancing novel bladder cancer treatments through clinical development and potential regulatory review.View CG Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to WatchQualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a CatchUber's Profit Drop: A Speed Bump or Structural Shift?Boeing Has the Orders, the Cash Flow, and Insider Buyers, But What's Still Missing?Keurig Dr Pepper's Beverage Growth Raises a Tough Question About Its Coffee SplitAmazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?Datadog's Post-Earnings Sell-Off: A Buying Opportunity in Plain Sight? Upcoming Earnings Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026)Honda Motor (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
